Differential expression of p53 and p504s in hyperplastic polyp, sessile serrated adenoma and traditional serrated adenoma

Abstract

Immunostains, p53 and P504S, may be useful adjuncts to morphological diagnosis of serrated polyps.

Clinicopathologic and Genetic Characterization of Traditional Serrated Adenomas of the Colon

“…7 Moreover, genetic progression in a TSA, characterized by the development of conventional epithelial dysplasia in association with abnormal nuclear accumulation of p53 protein, is significantly more common in TSAs that contain BRAF mutations than in those with KRAS mutations; p53 accumulation has also been described as a feature of SSAs with high-grade dysplasia. 24,25 We did not find a relationship of β-catenin nuclear labeling with genetic progression of TSAs as previously reported for SSAs. 10,12 However, our sample size was not sufficient to fully exclude this possibility, and intriguingly 2 (40%) of 5 TSADs did show nuclear labeling for β-catenin compared with only 2 (12%) of 17 TSAs.…”

Serrated Lesions of the Colorectum: Review and Recommendations From an Expert Panel

“…TSAs are much less common than SSA/Ps, so there are fewer data on their molecular profile (16, 48). TSAs appear to be more molecularly diverse than SSA/Ps in that they may have either KRAS or BRAF mutations or neither, and either low or high levels of CIMP.…”

Expression of olfactomedin 4 and claudin‐18 in serrated neoplasia of the colorectum: a characteristic pattern is associated with sessile serrated lesion

“…Thus, ancillary studies, such as demonstration of a distinct immunophenotype, might prove to be helpful tools if morphological assessment alone is not reliable enough in routine pathology practice. Currently, there are several immunohistochemical markers to assist conventional morphological diagnosis, including p53 and p504S, MLH1 and MSH2, cytokeratin 20 and Ki67, the profile of mucin core proteins such as MUC5AC, MUC2 and MUC6 and other molecular markers, including microRNA‐181b and microRNA‐21 . Serrated adenocarcinoma (SAC) represents an endpoint in the serrated neoplasia pathway and has been recognized as a distinct entity among CRCs, of which it makes up 7.5% .…”